{"nctId":"NCT01509547","briefTitle":"Varenicline for Adolescent Smoking Cessation","startDateStruct":{"date":"2012-08"},"conditions":["Nicotine Dependence"],"count":157,"armGroups":[{"label":"varenicline","type":"EXPERIMENTAL","interventionNames":["Drug: Varenicline"]},{"label":"placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"Varenicline","otherNames":["Chantix"]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age 14-21\n* Daily smoker for ≥6 months\n* Desire to quit smoking, with at least one prior failed quit attempt and willingness to participate in a treatment study\n* If under age 18, parent(s) or guardian(s) able to participate in informed consent and initial assessment (unless the participant provides evidence of emancipated status)\n* If female, agreement to use birth control (any form of hormonal contraception such as Depo-Provera, daily oral contraception, transdermal patch, or Nuva-ring; intrauterine device; sterilization; or double barrier contraception, which is a combination of any two of the following methods: condoms, spermicide, diaphragm) to avoid pregnancy\n\nExclusion Criteria:\n\n* Lifetime history of any DSM-IV-TR mood or psychotic disorder (e.g., major depressive disorder, bipolar disorder, schizophrenia)\n* Lifetime history of suicidality, homicidality, or clinically significant hostility/aggression\n* Current substance dependence, other than nicotine\n* Current unstable major medical disorder\n* Current pregnancy or breastfeeding\n* Current use of medications with smoking cessation efficacy\n* Known hypersensitivity to varenicline","healthyVolunteers":false,"sex":"ALL","minimumAge":"14 Years","maximumAge":"21 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Cotinine-confirmed 7-day Point Prevalence Abstinence at the End of Treatment","description":"Self-reported 7-day cigarette abstinence, confirmed by urine corinne ≤50 ng/mL at the end-of-treatment (week 12) visit","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Experiencing Treatment-emergent Adverse Events","description":"Clinician-collected adverse events (regardless of relatedness to medication) occurring at any point after randomization and initiation of treatment.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"60","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Visits With Abstinence During Treatment","description":"Self-reported between-visit abstinence at weekly visits during treatment (reported as percentage of total possible visits across all participants at which participants self-reported abstinence). Missing data were imputed to non-abstinence.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.2","spread":null},{"groupId":"OG001","value":"7.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Post-treatment Visits With Abstinence","description":"Self-reported abstinence at post-treatment follow-up visits (reported as percentage of total possible post-treatment follow-up visits at which abstinence in the prior week was self-reported). Missing data were imputed to non-abstinence.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.8","spread":null},{"groupId":"OG001","value":"10.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Achieving 7+ Days Abstinence at Any Point During Treatment","description":"Number of participants achieving 7+ days of self-reported abstinence at any point during active treatment","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":77},"commonTop":["nausea","viral upper respiratory tract infection","vomiting","headache","vivid dreams"]}}}